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Introduction {#sec1}
============

Astrocytes are functionally indispensable for normal brain activities ([@bib1], [@bib36], [@bib41]). Astrocytes play critical roles for the establishment and maintenance of functional neural networks through refining synapses, coordinating neuronal firing, maintaining the blood-brain barrier, as well as structural and metabolic support ([@bib10], [@bib28], [@bib36]). Functional loss or impairment of astrocytes is implicated in a wide range of pathological processes and neural disorders, including Alzheimer\'s disease, Huntington\'s disease, amyotrophic lateral sclerosis, and epilepsy ([@bib15], [@bib26], [@bib28]). In humans, astrocytes display unique hominid features ([@bib18]). Human astrocytes are morphologically larger, structurally more complex, and functionally more diverse than those in the rodent brain ([@bib18], [@bib22]). The complexity of human astrocytes allows for the increased functional competence of the adult human brain ([@bib18], [@bib22], [@bib37]). Thus, access to human astrocytes will substantially enable studies on the biology and pathology of astrocytes and facilitate therapeutic development.

Astrocytes have been successfully generated from human pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) ([@bib6], [@bib9], [@bib12], [@bib17], [@bib23], [@bib20], [@bib27], [@bib34], [@bib43]) ([Table S1](#mmc1){ref-type="supplementary-material"}). These methods are based on developmental principles to expand the neural progenitors until gliogenesis ([@bib29], [@bib33]). Hence, the differentiation process ranges from 3 to 6 months. There are reports on astrocyte generation in a shorter time but the identity and functional properties of the astrocytes are less rigorously examined ([Table S1](#mmc1){ref-type="supplementary-material"}). The main reason for this long process is that we lack effective ways to promote the gliogenic program of the neural progenitors and, as a result, wait for the progenitors to become gliogenic by "default." Such an approach also results in variations in the differentiated products.

One way to accelerate the differentiation process is to force the expression of cell-type-specific transcription factors in stem cells. This has been demonstrated by fast (2--4 weeks) generation of functional neurons from human ESCs (hESCs) through virus-mediated expression of a proneural gene, *Ngn2* ([@bib42]). In this study, using a similar strategy, we created hESC and iPSC lines with inducible expression of gliogenic transcription factors *NF1A* or *NF1A* plus *SOX9* via CRISPR/Cas9. Utilizing inducible expression of *NF1A* or *NF1A* plus *SOX9*, we developed a method for fast generation of homogeneous functional and transplantable astrocytes from hESCs and iPSCs in 4--7 weeks. Importantly, by patterning with morphogens during the induction, we developed a method to generate region-specific subtype astrocytes in the same time frame.

Results {#sec2}
=======

Expression of *NFIA* Facilitates Astrocyte Differentiation from hPSCs {#sec2.1}
---------------------------------------------------------------------

The *NFI* (nuclear factor I) family transcription factors are crucial for the initiation of gliogenesis and acquisition of gliogenic competence in the developing CNS ([@bib5], [@bib11], [@bib14], [@bib35], [@bib38]). To determine if *NFI* promotes astrocyte differentiation from human stem cells, we established hESC lines with inducible expression of *NFIA*. This was achieved by targeting TRE3G-*NFIA* in the AAVS1 locus by CRISPR/Cas9 ([@bib21]) ([Figure 1](#fig1){ref-type="fig"}A). After drug selection and PCR verification, colonies were grown and cultured \>3 passages before being subjected to induced expression of *NFIA* by adding doxycycline (DOX). Upon induction with DOX for 72 hr, *NFIA* mRNA and protein were robustly expressed, as indicated by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}B) and immunocytochemistry ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Astrocyte Differentiation Induced by NFIA Expression(A) Schematic depiction of the strategy for constructing and targeting TRE3G-*NFIA* into the AAVS1 locus.(B) qRT-PCR analysis of induced expression of *NFIA*. n = 3 replicate reactions.(C) Immunostaining analysis of induced expression of *NFIA*. Scale bar, 200 μm.(D) Diagram of the facilitated generation of astrocytes by *NFIA* induction. Stage 1, neural fate commitment by dual SMAD inhibition; stage 2, astrocyte progenitor induction by a suspension culture; stage 3, astrocyte specification and maturation on a monolayer culture.(E) Representative images and quantification of induced GFAP+ cells after 52 or 67 days of differentiation. n = 3 independent experiments (with replicate wells) were analyzed. Scale bars, 100 μm.(F) Induced cells co-expressed GFAP and S100β. Scale bar, 100 μm. Data of this figure are produced by using the TRE3G-NFIA hPSCs (H9).The data are presented as the means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01 (Student\'s t test).

Previously, we developed the method of directed differentiation of hPSCs into astrocytes, in which GFAP-expressing astrocytes begin to appear at around 3 months and reach a peak at 6 months ([@bib12]). In this method, the hPSCs were committed in monolayer culture into the neural fate by SMAD inhibition as stage 1, then the cells were floated as neural progenitors in culture with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) for as long as 5--6 months for the neural-to-glia developmental fate switch as stage 2, and plated down for astrocytic maturation as stage 3. To determine the effect of *NFIA*, we used the same differentiation scheme but with induced *NFIA* expression from the start of differentiation by DOX, and then subjected the induced cells to a 7-day maturation ([Figure 1](#fig1){ref-type="fig"}D). By weekly examination in stage 2, we found that about 20% GFAP+ cells were generated at 45 days of induction plus a 7-day maturation ([Figures 1](#fig1){ref-type="fig"}E and 1F). In contrast, the control group (without DOX) generated less than 3% GFAP+ astrocytes ([Figure 1](#fig1){ref-type="fig"}E). By extending the induction to 67 days, the GFAP+ cell population was further increased to 40%--50%, and the cells were larger with more processes than the induced cells at day 52 ([Figure 1](#fig1){ref-type="fig"}E). The astrocytic identity was further confirmed by its co-expression with S100β, another astrocyte-associated gene ([Figure 1](#fig1){ref-type="fig"}F). These results indicate that *NF1A* expression substantially speeds up the astrocyte differentiation from hESCs.

Expression of *NFIA* and *SOX9* Further Accelerates Astrocyte Differentiation {#sec2.2}
-----------------------------------------------------------------------------

Besides *NFIA*, *SOX9* is another determining factor for the astroglial cell fate ([@bib11], [@bib30], [@bib38]). *NFIA* and *SOX9* form a complex to coordinate a transcriptional regulatory cascade for initiating gliogenesis during neural development ([@bib11]). Astrocytic fates can be induced from neural progenitor cells *in vivo* or from cultured mouse fibroblasts by overexpressing *NFI* + *SOX9* ([@bib7]). To determine if the combination of *NFIA* and *SOX9* further accelerates the astrocyte differentiation, we generated hESC lines with inducible expression of *NFIA* and *SOX9* by targeting the Tet3G-*NFIA* + *SOX9* into the AAVS1 locus using the same approach ([Figure 2](#fig2){ref-type="fig"}A). Again, the mRNA and protein of both genes were reliably induced by DOX ([Figures 2](#fig2){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}A). Western blotting indicated that NFIA expression was higher in the NFIA + SOX9 line than the NFIA line ([Figure S1](#mmc1){ref-type="supplementary-material"}C). This result is consistent with the previous report that NFIA expression is regulated and reinforced by SOX9 to coordinate a transcriptional regulatory cascade for the initiation of gliogenesis ([@bib11]). Quantification of the immunostained cells showed that over 90% of the cells expressed either NFIA or SOX9, indicating that the vast majority of the cells co-expressed NFIA and SOX9 ([Figures 2](#fig2){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B).Figure 2Astrocyte Differentiation Induced by Expression of *NFIA* and *SOX9*(A) Schematic depiction of the strategy for constructing and targeting TRE3G-*NFIA* + *SOX9* into the AAVS1 locus.(B) Immunostaining analysis of induced expression of *NFIA* and *SOX9*. Scale bar, 200 μm.(C) Quantification of positive cells with the induced expression of *NFIA* in NFIA-hPSC line (NFIA+ in NFIA-PSC) and *NFIA* or *SOX9* in NFIA + SOX9 hPSC line (NFIA+ and SOX9+ in NFIA-PSC). PSC colonies from n = 3 replicate cultures were analyzed.(D) Diagram of the facilitated generation of astrocytes by *NFIA* and *SOX9* induction. Stage 1, neural fate commitment by dual SMAD inhibition; stage 2, astrocyte progenitor induction by a suspension culture; stage 3, astrocyte specification and maturation on a monolayer culture.(E) Representative images and quantification of induced GFAP+/S100β+ cells after 52 days of differentiation. n = 3 independent experiments (with replicate wells) were analyzed. Scale bar, 50 μm. Data in this figure were produced using the TRE3G-NFIA + SOX9 hPSCs (H9). The data are presented as the means ± SEM.

The astrocyte induction and maturation was performed in the same way as for *NFIA* lines ([Figure 2](#fig2){ref-type="fig"}D). After 37 days' induction, around 30% of the cells became GFAP+ ([Figure S1](#mmc1){ref-type="supplementary-material"}D). With extended (52 days) induction of *NF1A* and *SOX9*, 70%--80% of the cells became GFAP+ ([Figure 2](#fig2){ref-type="fig"}E). The astrocytic identity of the induced cells was confirmed by their co-expression of GFAP and S100β ([Figure 2](#fig2){ref-type="fig"}E). The efficiency and identity of the induced cells were reproducible using different engineered hESC clones ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Thus, expression of *NF1A* and *SOX9* results in a substantially shorter period for generation of astrocytes than that by regular differentiation, which takes 6 months to generate equivalent percentage of GFAP+ cells ([@bib12]).

To validate the applicability of this strategy, we established two transgenic iPSC lines (WC50 and IMR90) with inducible expression of *NF1A* and *SOX9* using the same approach described above ([Figures S2](#mmc1){ref-type="supplementary-material"}A, S2B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Again, induced astrocytes were efficiently generated from the two iPSC lines ([Figures S2](#mmc1){ref-type="supplementary-material"}C and [S3](#mmc1){ref-type="supplementary-material"}C).

Our time course analysis indicated that the GFAP-expressing astrocytes increase from day 37 to 52 with induction of NF1A or NF1A + SOX9. When we further extended the induction of NF1A and SOX9 for another 60 days, we found that the population of GFAP-expressing astrocytes increased from 80% to 90% ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We noticed that, even at the extended culture, some cells, with expression of S100β and an astrocyte morphology, remained negative or only weakly positive for GFAP ([Figure S4](#mmc1){ref-type="supplementary-material"}A). It has been reported that not all astrocytes express GFAP ([@bib39]).

We then asked if the phenotypes of the induced astrocytes are stable when the transgene expression is stopped. We withdrew DOX at day 52 and continued the culture for another 14 days. The induced cells retained their expression of GFAP and S100β ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Furthermore, these induced astrocytes promoted the growth of neurites, including the length and branching ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Thus, the induced cells retain the identity and function of astrocytes. We refer the induced astrocytes from TRE3G-NFIA + SOX9 hPSC lines after a 52-day induction as iAstro.

The iAstro Display Molecular Signatures of Astrocytes {#sec2.3}
-----------------------------------------------------

Under our culture condition, the iAstro displayed a star-shaped morphology with delicate processes ([Figures 2](#fig2){ref-type="fig"}E and [3](#fig3){ref-type="fig"}A). Immunocytochemical analysis showed that the induced astrocytes co-expressed astrocyte markers, including S100β, ALDH1L1, CD44, and Connexin43 (CX43) ([Figure 3](#fig3){ref-type="fig"}A).Figure 3Cellular and Molecular Characterization of iAstro(A) Representative images of iAstro, showing co-expression of GFAP with ALDH1L1, CD44, and CX43.(B) Hierarchical clustering analysis of RNA sequencing data from the iAstro, non-transgenically induced cells, and primary astrocytes.(C) Heatmap profiling of astrogenic and neurogenic genes, mesoderm gene (Brachyury) and endoderm gene (SOX17).(D) Representative images of transplanted iAstro, showing human-specific GFAP+/S100β+ (hGFAP+/S100β+) and hGFAP−/S100β+ host astrocytes. Arrowhead indicates graft and arrow indicates a host astrocyte. Scale bars, 100 μm.(E) Representative images of transplanted iAstro (indicated by human-specific cytoplasm marker, Stem121, arrowhead) co-expressing SOX9 and CX43. The area indicated by the yellow arrowhead in the upper row is amplified on the right.Scale bars, 100 μm. Data in this figure were produced using the TRE3G-NFIA + SOX9 hPSCs (H9).

If induced transgene expression contributes to the glial differentiation, it is expected that the methylation status of the GFAP promoter is demethylated. Methylation analysis on the GFAP promoter by bisulfite sequencing indicated that the GFAP promoter was methylated in hPSCs but demethylated in the iAstro after induction with NFIA and SOX9 ([Figure S4](#mmc1){ref-type="supplementary-material"}D). This epigenetic change in the GFAP promoter region coincides with transgene-induced glial differentiation.

To further define the identity of the iAstro, we performed RNA-sequencing (RNA-seq) analysis. Hierarchical clustering analysis or principal-component analysis showed that iAstro were placed close to the primary astrocytes but distant from the non-transgene-induced cells, which are mostly neural progenitors ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}E). Compared with the cells without transgenic induction, the iAstro enriched the expression of astrocyte signature genes, including GFAP, S100β, ALDH1L1, and others ([Figure 3](#fig3){ref-type="fig"}C). In contrast, the expression of neuronal genes (e.g., NEFL, NEFM, and NEUN) was suppressed ([Figure 3](#fig3){ref-type="fig"}C). Gene ontology analysis further revealed that the upregulated genes after transgenic induction were mainly enriched in cell-cell signaling, extracellular matrix and cell adhesion, inflammatory response, and K+ ion transmembrane transport, whereas the downregulated genes were mainly involved in neuronal fate differentiation, forebrain cell proliferation, synaptic transmission, peptide signaling pathways, neuronal migration, and long-term synaptic potentiation ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Together, these results further validate that the iAstro are indeed astrocytes but not neurons, oligodendrocytes, or neural progenitors.

To determine whether the iAstro retain the astrocyte identity *in vivo*, we transplanted the iAstro after a 52-day induction into the corpus callosum and cerebral cortex of adult severe combined immunodeficiency mice. Three months following transplantation, the grafted astrocytes were detected, as indicated by human-specific GFAP (hGFAP) ([Figure 3](#fig3){ref-type="fig"}D). The hGFAP+ cells were larger with elaborated processes compared with the endogenous mouse astrocytes that were labeled by S100β ([Figure 3](#fig3){ref-type="fig"}D). Furthermore, the transplanted human cells, as indicated by the expression of human-specific cytoplasm protein Stem121 ([@bib4]), were also positive for SOX9 and CX43 ([Figure 3](#fig3){ref-type="fig"}E), markers expressed by mature astrocytes ([@bib23], [@bib31], [@bib40]). Thus, the *in vitro* generated iAstro retain the astrocyte identity *in vivo*.

The iAstro Display Functional Properties of Astrocytes {#sec2.4}
------------------------------------------------------

*In vitro*, astrocytes are known to support neurite growth. We induced the neurons from EGFP hPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}F). These resulting EGFP neurons were plated on to the iAstro or alone for 5 days. Measurement of the GFP+ neurites by ImageJ revealed that the neurons co-cultured with the iAstro developed significantly more and longer neurites compared with those without astrocyte co-culture ([Figure 4](#fig4){ref-type="fig"}A). A similar phenomenon was observed when using the iAstro derived from the transgenic iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}G) or primary fetal human astrocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}H).Figure 4Functional Characterization of iAstro(A) Quantification of neurite outgrowth from neurons alone or neurons co-culturing with iAstro. n = 3 independent experiments (with replicate wells) were analyzed. Scale bar, 100 μm.(B) Images of calcium wave propagation over the duration of mechanical stimulation. Asterisk indicates the site of stimulation. Scale bar, 50 μm.(C) Expression of ETTA1 and ETTA2 in iAstro and the kinetics of cellular uptake of glutamate from the medium. The expression of ETTA1 and ETTA2 are normalized to control cells (w/o DOX). n = 2 replicates for fold expression analysis. n = 8 replicate wells for glutamate uptake analysis and the data are presented as the means ± SEM.^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (Student\'s t test). Data in this figure were produced using the TRE3G-NFIA + SOX9 hPSCs (H9).

Calcium wave propagation across astrocytes is critical for neuron-glia and glia-glia communication ([@bib24]). When the iAstro derived from TRE3G-NFIA + SOX9 hPSCs (H9) were loaded with Fluor 4 and mechanically stimulated by a pipette, intracellular calcium waves and spikes were instantaneously induced from the stimulation site ([Figure 4](#fig4){ref-type="fig"}B). A similar phenomenon was observed when using the primary fetal human astrocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}H). These calcium waves of iAstro traveled outward to adjacent cells at a speed of 10 ± 1.63 μm/s ([Figure S4](#mmc1){ref-type="supplementary-material"}F), which is faster than primary adult mouse astrocytes *in vivo* (8.6 ± 0.6 μm/s) and slower than primary adult human astrocytes *in vivo* (43.4 ± 4.7 μm/s) ([@bib18]).

Astrocytes play a critical role in maintaining the homeostatic brain environment by taking up neurotransmitters. The mRNA expression of glutamate transporters, especially EAAT1, increased significantly after the transgenic induction by DOX ([Figure 4](#fig4){ref-type="fig"}C). To determine if the glutamate transporters are functional, we measured glutamate uptake by the iAstro from the culture medium. The iAstro took up glutamate at a rate of 754 ± 214 nM/min. As a comparison, the glutamate uptake by primary astrocytes was 1,066 ± 235 nM/min ([Figure 4](#fig4){ref-type="fig"}C). Thus, the iAstro take up glutamate similarly as primary astrocytes.

Fast Generation of Subtype Astrocytes {#sec2.5}
-------------------------------------

To determine the optimal window of transcription factor-induced astrocyte differentiation, we titrated the duration of DOX application for inducing iAstro from TRE3G-NFIA + SOX9 hPSCs (H9). We found that the induced transgenic expression in stage 2 (day 10 to 45) was indispensable for facilitating astrocyte generation, and the transgenic expression in stage 3 (7-day maturation) further enhanced the efficiency ([Figure 5](#fig5){ref-type="fig"}A). In contrast, stage 1 (neuroepithelial induction from day 1 to 10) is dispensable ([Figure 5](#fig5){ref-type="fig"}A). This result suggests that NF1A or NF1A plus SOX9 promotes astrocyte differentiation from specified neural progenitors.Figure 5Fast Generation of Region-Specific Astrocyte Subtypes from hPSCs(A) Optimal window of transcription factor expression for fast induction of astrocytes. n = 3 independent experiments (with replicate wells) were analyzed. Stage 1, neural fate commitment by dual SMAD inhibition; stage 2, astrocyte progenitor induction by suspension culture; stage 3, astrocyte specification and maturation on monolayer culture.(B) Schematic strategy for fast generation of subtype astrocytes. Examples include fast generation of cortical, ventral forebrain, and hindbrain/spinal cord astrocytes.(C) Regionally specified cell identity with region-specific markers: OTX2 (forebrain), NKX2.1 (ventral), and HOXB4 (spinal). The astrocyte identity of the induced subtype cells was verified by co-immunostaining with the astrocyte marker GFAP.Scale bar, 100 μm. Data in this figure were produced using the TRE3G-NFIA + SOX9 hPSCs (H9).

In stage 1 of astrocyte differentiation (day 1--10), hPSCs are specified to neuroepithelia which are readily patterned to regional progenitors by morphogens ([@bib13], [@bib33]). We hence asked if regional astrocyte types may be generated at the same speed when the early neuroepithelia are patterned with respective morphogens in stage 1. We differentiated the hPSCs to neuroepithelia in the presence of morphogens for 10 days before induced expression of transgenes for iAstro generation ([Figure 5](#fig5){ref-type="fig"}B). In the absence of morphogens, the resulting iAstro (around 70%) were of mostly dorsal forebrain (cortical) identity, as indicated by expression of the forebrain marker OTX2 ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}). In the presence of ventral patterning morphogen, sonic hedgehog (Shh), a proportion (around 50%) of GFAP+ cells expressed NKX2.1, a ventral forebrain marker ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}). In the presence of caudal patterning morphogen retinoic acid (RA), they (\>80%) became spinal astrocytes at day 52, as indicated by their co-expression of GFAP and HOXB4 ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}). Thus, iAstro with different regional identities are generated at the same speed by combining patterning of neuroepithelia and induction of NF1 and SOX9.

Discussion {#sec3}
==========

We have developed a robust method to generate functional astrocytes from hESCs and hiPSCs in 4--7 weeks. This is achieved by CRISPR/Cas9-mediated inducible expression of the gliogenic transcription factors *NFIA* or *NFIA* + *SOX9* in stem cells. The induced cells (or iAstro) exhibit characteristic cellular and functional properties of astrocytes and retain their identity after withdrawal of transgene expression and following transplantation into the mouse brain. Importantly, our method can be extended to generation of astrocyte subtypes in the same time frame by combining regional patterning of neural progenitors and induction of transgenes. This simple and efficient method is substantially faster than the regular differentiation methods mimicking astrocyte development that take 3--6 months ([@bib12]) and thus helps facilitate the study on human astrocyte biology.

Gliogenesis is a late event during neural development. In humans, it begins at 3 months into gestation and continues for many months. Accordingly, available methods for differentiating hPSCs to astrocytes takes 3--6 months by mimicking the developmental process ([@bib12]). This is because we lack a non-genetic means to switch the neurogenic progenitors to the gliogenic phase. From the standpoint of developmental biology, gliogenic transcription factors, including *NFIA* and *SOX9*, initiate gliogenesis and maintain the glial identity during neural development ([@bib5], [@bib11], [@bib14], [@bib30], [@bib35], [@bib38]). Forced expression of *NFI* and *SOX9* in neuronal progenitor cells *in vivo* or in cultured mouse fibroblasts promotes astrocyte generation ([@bib7]). By expressing *NFIA* during hPSC neural differentiation, we are now able to generate astrocytes substantially earlier. The addition of *SOX9* further accelerates the differentiation of astrocytes. This is likely due to the coordinated effect of *NFIA* and *SOX9* in initiating gliogenesis ([@bib11]). Indeed, our RNA-seq analysis shows that NF1A and SOX9 repress neuronal differentiation and facilitate glial differentiation. This is also indicated by the methylation assay, showing that the GFAP promoter is demethylated after the transgenic induction, which enables the cells to express the gliogenic gene GFAP during the iAstro differentiation.

Astrocytes in different brain regions exhibit differential properties ([@bib8], [@bib25], [@bib28], [@bib32], [@bib41]). We have shown that the iAstro with regional identities can be generated by patterning the early neural progenitors during regular differentiation ([@bib12]). However, forced expression of neural transcription factors at the beginning of differentiation skips the neural patterning step, resulting in the generation of mature neurons, as demonstrated by *Ngn2*-induced neurons ([@bib42]). Interestingly, we found that, for iAstro generation, the expression of *NF1A* and *SOX9* is dispensable at the early stage of neural differentiation, suggesting that they act on specified neuroepithelia for astrocyte differentiation. This opens a window of opportunity for us to pattern the early neuroepithelia with respective morphogens for generation of region-specific progenitors before driving the progenitors to iAstro through induction of *NF1A* and *SOX9*. The combination of neural induction/patterning and expression of *NF1A* and *SOX9* enables fast generation of subtypes of functional astrocytes (iAstro).

The functional properties of astroglial subtypes in the adult CNS remain largely undefined ([@bib1], [@bib16], [@bib19]). It has been demonstrated that region-specific astrocytes (e.g., cortical or subcortical) selectively promote neurite growth of neurons from the corresponding region ([@bib16]). The gap junction coupling strength appears higher in astrocytes from hippocampus and hypothalamus than those from cerebral cortex and brain stem ([@bib2]). Calcium waves in gray matter protoplasmic astrocytes rely on gap junction coupling to propagate, while fibrous astrocytes of the white matter in the corpus callosum propagate calcium waves depending on ATP ([@bib19]). The ability to generate mature astrocyte subtypes from hPSCs will facilitate the investigation of the functional diversity of region-specific astrocytes.

The generation of clonal hPSC lines through CRISPR-mediated transgenesis enables regulation of transgenes in a consistent and reproducible manner, thus producing homogeneous cell populations. This method is simple and can be readily applied to patient iPSCs. The inducible hPSC lines can also be introduced with disease-related mutations for studying the roles of astrocytes in pathogenesis. Hence, the method is advantageous over virus-mediated approaches that involves random transgene integration.

The iAstro exhibit characteristic astrocyte morphology, express astrocytic markers, and maintain their identity after withdrawal of transgenes and transplantation into the mouse brain. Functionally, they resemble primary astrocytes, propagating calcium waves, taking up glutamate, and supporting neurite growth. Therefore, the iAstro are appropriate for studying the biology of human astrocytes as well as their interactions with surrounding neurons and glia under physiological and pathological conditions. Their ability to survive and integrate into the mouse brain makes it appropriate to analyze the behaviors of the iAstro *in vivo*.

Experimental Procedures {#sec4}
=======================

hPSC Culture {#sec4.1}
------------

HESCs (line H9, passages 20--40) and iPSCs lines (WC50 and IMR90; see also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) were cultured as described previously ([@bib12]). In brief, cells were passaged weekly by using dispase (1 mg/mL, Gibco) and plating on a monolayer of irradiated mouse embryonic fibroblasts (WiCell). The hPSC culture medium consisted of DMEM/F12 basal medium (Gibco), 20% KnockOut serum replacement (Gibco), 0.1 mM β-mercaptoethanol (Sigma), 1 mM L-glutamine (Gibco), nonessential amino acids (Gibco), and 4 ng/mL FGF-2 (R&D Systems).

### Fast Induction of Subtype Astrocytes from Engineered hPSC Lines {#sec4.1.1}

TRE3G-*NFIA*/TRE3G-*NFIA* + *SOX9* hPSC lines were established (detailed in the [Supplemental Information](#app2){ref-type="sec"}) and first differentiated to neuroepithelia in the presence of DMH1 (2 μM, Tocris) plus SB431542 (2 μM, Tocris) for 10 days as reported ([@bib3], [@bib9]). The cells were digested by EDTA (Gibco) and proceeded into stage 2 induction in suspension in T25 flasks as described above: heparin (1 μg/mL, Sigma) is added in the first week of stage 2 with FGF-2 (10 ng/mL, R&D) and then the cells were cultured with FGF-2 (10 ng/mL, R&D) plus EGF (10 ng/mL, R&D) until stage 3 for maturation. For fast differentiation to cortical astrocytes, the culture was continued without additional regionally patterning factors; for fast differentiation to ventral forebrain astrocytes, Shh (500 ng/mL, R&D Systems) was added (day 0--21); for fast differentiation to spinal astrocytes, RA (500 nM, Tocris) was added (day 0--21). All the groups were treated with DOX (1 μg/mL) from day 11 to induce astrocyte differentiation. After 45 days of induction, the cells were dissociated with Accutase (Chemicon) and attached to Matrigel-coated plates at a density of 5,000--10,000/cm^2^ in the presence of BMP4 (10 ng/mL) and CNTF (10 ng/mL) for another 7 days for maturation. For cell transplantation, all procedures were approved by the Animal Care and Use Committee of University of Wisconsin-Madison.
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